Insulin resistance and lipotoxicity - 2 facets of one problem

• Alexander S. Ametov
• Ekaterina A. Tertychnaya

Abstract

The review presents an analysis of clinical and experimental data on the pathogenetic mechanisms of insulin resistance and lipotoxicity in diabetes mellitus. The paper presents their interrelation and role in the development of carbohydrate metabolism disorders from the position of the theory of limited adipose tissue expandability. The protective properties of adiponectin were also analyzed due to its ability to increase insulin sensitivity, stimulation of oxidation of free fatty acids in the liver and muscles. Pharmacotherapy of insulin resistance and lipotoxicity is currently limited. The locally produced hypoglycemic complex drug, containing antibodies to the C-terminal β-subunit of the insulin receptor and to endothelial NO synthase in a special technological form named as «released-active form» showed an ability to increase insulin sensitivity and adiponectin production, which allows to use it as an additional component of hypoglycemic therapy.

Keywords:obesity, diabetes mellitus, insulin resistance, lipotoxicity, free fatty acids, adiponectin

References

1. Dedov I.I., Shestakova M.V., Vikulova O.K. Epidemiology of diabetes the federal diabetes registry. Sakharni diabet [Diabetes Mellitus]. 2017; mellitus in Russian Federation: clinical and statistical report according to 20 (1): 13-41. (in Russian)

2. The Ministry of Health called the regions suffering from obesity https://www.rbc.ru/society/24/07/2018/5b519ee49a7947f2d4d7fa9b (in Russian)

3. Hajer G.R., wan Haeften T.W., Visseren F.L. Adipose tissue disfunction in obesity, diabetes and vascular diseases. Eur Heart J. 2008; 29 (24): 2959-71. doi: 10.1093/eurheartj/ehn387

4. Dedov 1.1., Melnichenko G.A., Butrova S.A. Adipose tissue as an endocrine organ. Ozhirenie i metabolism [Obesity and Metabolism]. 2006; (1): 6-13. (in Russian)

5. Guo Z., Hensrud D.D., Johnson C.M., Jensen M.D. Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes.1999; 48 (8): 1586-92.

6. Ebbert J.O., Jensen M.D. Fat depots, free fatty acids, and dyslipidemia. Nutrients. 2013; 5 (2): 498-508.

7. Unger R.H. Lipotoxic diseases. Ann Rev Med. 2002; 53: 319-36.

8. Korani M., Firoozrai M., Maleki J., et al. Fatty acid composition of serum lipids in patients with type 2 diabetes. Clin Lab. 2012; 58 (1112): 1283-91.

9. Bajaj M., Suraamornkul S., Romanelli A., Cline G.W., et al. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty acyl-coAs and insulin action in type 2 diabetic patients. Diabetes. 2005; 54 (11): 3148-53.

10. Cusi K., Kashyap S., Gastaldelli A., et al. Effect on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Metab. 2007; 292: 1775-8.

11. Brans C., Grunnet L.G. Mechanisms in endocrinology: Skeletal muscle lipotoxicity in insulin resistance and type 2 diabetes: a causal mechanism or an innocent bystander? Eur J Endocrinol. 2017; 176 (2): 67-78.

12. Samuel V.T., Shulman G. Mechanisms for insulin resistance: Common threads and missing links. Cell. 2012; 148: 852-71.

13. Turinsky J., Bayly B.P., O’Sullivan D.M. 1,2-Diacylglycerol and ceramide levels in rat skeletal muscle and liver in vivo. Studies with insulin, exercise, muscle denervation, and vasopressin. J Biol Chem. 1990; 265 (14): 7933-8.

14. Summers S.A. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res. 2006; 45 (1): 42-72.

15. Veret J., Coant N., Berdyshev E.V., Skobeleva A., et al. Ceramide synthase 4 and de novo production of ceramides with specific N-acyl chain lengths are involved in glucolipotoxicity-induced apoptosis of INS-1 β-cells. Biochem J. 2011; 438 (1): 177-89.

16. Boslem E., Weir J.M., Macintosh G., Sue N., et al. Alteration of endoplasmic reticulum lipid rafts contributes to lipotoxicity in pancreatic β-cells. J Biol Chem. 2013; 288 (37): 26569-82.

17. Shimabukuro M., Zhou Y.T., Levi M., Unger R.H. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA. 1998; 95 (5): 2498-502.

18. Engin A.B. What is lipotoxicity? Adv Exp Med Biol. 2017; 960: 197-220. doi: 10.1007/978-3-319-48382-5_8

19. Walther T.C., Farese R.V. Jr. The life of lipid droplets. Biochim Biophys Acta. 2009; 1791: 459-66.

20. Aon M.A., Bhatt N., Cortassa S.C. Mitochondrial and cellular mechanisms for managing lipid excess. Front Physiol. 2014; 5: 282.

21. Lowell, B.B., and G.I. Shulman. Mitochondrial dysfunction and type 2 diabetes. Science. 2005; Vol. 307: 384-7.

22. Petersen, K.F., Befroy D., Dufour S., Dziura J., et al. Mitochondrial dysfunction in the elderly: Possible role in insulin resistance. Science. 2003; 300: 1140-2.

23. Gao D., Nong S., Huang X., Lu Y., et al. The effects of palmitate on hepatic insulin resistance are mediated by NADPH Oxidase 3-derived reactive oxygen species through JNK and p38MAPK pathways. J Biol Chem. 2010; 285 (39): 29965-73.

24. Aguirre V., Uchida T., Yenush L., Davis R., White M.F. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem. 2000; 275 (12): 9047-54.

25. Ye R., Jung D.Y., Jun J.Y., Li J., et al. Grp78 heterozygosity promotes adaptive unfolded protein response and attenuates diet-induced obesity and insulin resistance. Diabetes. 2010; 59: 6-16.

26. Lee M.W., Chanda D., Yang J., Oh H., et al. Regulation of hepatic gluconeogenesis by an ER-bound transcription factor, CREBH. Cell Metabolism. 2010; 11 (4): 331-9.

27. Seifert E.L., Estey C., Xuan J.Y., Harper M.E. Electron transport chain-dependent and -independent mechanisms of mitochondrial H₂O₂ emission during long-chain fatty acid oxidation. J Biol Chem. 2010; 285: 5748-58.

28. Ghosh J., Das J., Manna P., Sil P.C. Taurine prevents arsenic-induced cardiac oxidative stress and apoptotic damage: Role of NF-kappa B, p38 and JNK MAPK pathway. Toxicol Appl Pharmacol. 2010; 240: 73-87.

29. Banhegyi G., Benedetti A., Csala M., Mandl J. Stress on redox. FEBS Letters. 2007; 581: 3634-40.

30. Lam T.K., Yoshii H., Haber C.A., Bogdanovic E., et al. Free fatty acid-induced hepatic insulin resistance: A potential role for protein kinase C-delta. Am J Physiol Endocrinol Metab. 2002; 283 (1): E682-91.

31. Berg A.H., Combs T.P., Du X., et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001; 7: 947-53.

32. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7: 941-6.

33. Holland W.L., Miller R.A., Wang Z.V., et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 2011; 17: 55-63.

34. Xia J.Y., Holland W.L., Kusminski C.M., et al. Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis. Cell Metab, 2015; 22: 266-78.

35. Qi Y., Takahashi N., Hileman S.M. et al. Adiponectin acts in the brain to decrease body weight. Nat Med. 2004; 10: 524-9.

36. Kusminski C.M., McTernan P.G., Schraw T., et al. Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum. Diabetologia. 2007; 50: 634-42.

37. Despres J.P., Golay A., Sjostrom L. Rimonabant in Obesity-Lipids Study Group: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005; 353: 2121-34.

38. Kadowaki T., Yamauchi T., Kubota N., Hara K., et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006; 116: 1784-92.

39. Snijder M.B., Heine R.J., Seidell J.C., Bouter L.M., et al. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn study. Diabetes Care. 2006; 29: 2498-503.

40. Ametov A.S. Obesity. Modern view on pathogenesis and therapy. Vol. 1. Moscow: GEOTAR-Media, 2019: 384 p. (in Russian)

41. Vorob’yev S.V., Petrovskaya E.U., Kuz’menko N.A., Khripun I.A. А new drug in the complex therapy of diabetes mellitus. post-registration experience in patients with type 1 and type 2 diabetes mellitus. Meditsinskiy sovet [Medical Council]. 2018; (16): 28-34. (in Russian)

42. Gorbunov E.A., Nicoll J., Myslivets A.A., Kachaeva E.V., Tarasov S.A. Subetta enhances sensitivity of human muscle cells to insulin. Bull Exp Biol Med. 2015; 159 (4): 463-5.

43. Gorbunov E.A., Nicoll J., Kachaeva E.V., Tarasov S.A., Epstein O.I. Subetta increases phosphorylation of insulin receptor β-subunit alone and in the presence of insulin. Nutr. Diabetes. 2015. Vol. 5, N 7. P e169. doi:10.1038/nutd.2015.20

44. Belous A.S., Pokrovskaya T.G., Pokrovsky M.V., et al. Studying of cardioprotective effects of mix of homeopathic dilutions of polyclonal rabbit antibodies to endothelial synthase of nitrogen oxide (eNOS) C12, C30, C200 at experimental modeling of L-NAME of the induced deficiency of oxide. In: Abstracts of the reports of reports of the XIV Russian National Congress "Man and Drug". Moscow; 2007. (in Russian)

45. Pokrovsky M.V., Kochkarov V.I., Pokrovskaya T.G., et al. Comparative study of potential endothelium protectors and Impaza drug in nitric oxide deficiency simulation. Byulleten' eksperimental'noy biologii i meditsiny [Bulletin of Experimental Biology and Medicine]. 2009; 148 (8; Suppl): 154-8. (in Russian)

46. Nicoll J., Gorbunov E.A., Tarasov S.A., Epstein O.I. Subetta treatment increases adiponectin secretion by mature human adipocytes in vitro. Int J Endocrinol. 2013; 2013: 925874.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)